These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 32621434)

  • 1. [Brief Introduction to Regulatory Documents of European and American Drug-Device Combinations and Enlightenment].
    Luo Q; Tian J; Wang Y
    Zhongguo Yi Liao Qi Xie Za Zhi; 2020 Mar; 44(3):246-248. PubMed ID: 32621434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.
    Coppens DGM; de Wilde S; Guchelaar HJ; De Bruin ML; Leufkens HGM; Meij P; Hoekman J
    Cytotherapy; 2018 Jun; 20(6):769-778. PubMed ID: 29730080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The EU medical device market process and enlightenment for the review].
    Luo Q
    Zhongguo Yi Liao Qi Xie Za Zhi; 2014 May; 38(3):210-2. PubMed ID: 25241519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Discussion of Enlightenment from the Reorganization of CDRH Regulatory for Medical Device].
    Shang H; Zhang S
    Zhongguo Yi Liao Qi Xie Za Zhi; 2020 Feb; 44(2):154-157. PubMed ID: 32400990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chaos to Clarity: Pragmatic Approaches to Overcome Challenges for Successful Implementation of Additional Risk Minimisation Measures in the European Union and the UK by a Marketing Authorisation Holder.
    Hapani K; Parikh N; Pianka K; Patel H
    Pharmaceut Med; 2022 Jun; 36(3):173-188. PubMed ID: 35416591
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety-related regulatory actions for biologicals approved in the United States and the European Union.
    Giezen TJ; Mantel-Teeuwisse AK; Straus SM; Schellekens H; Leufkens HG; Egberts AC
    JAMA; 2008 Oct; 300(16):1887-96. PubMed ID: 18940975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Better medical devices regulations for better health care: enlightenment for medical devices regulatory reform in China, from experiences of the E.U. and the U.S.A].
    Sun Q; Yan L
    Zhongguo Yi Liao Qi Xie Za Zhi; 2006 Jan; 30(1):43-52. PubMed ID: 16646425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Discussion on Technical Evaluation Requirements of Allergen Detection Reagent Pre-marketing].
    Yang XH; Dong QF; Zhang L; Wang YH; Zhu WW
    Zhongguo Yi Liao Qi Xie Za Zhi; 2022 May; 46(3):318-322. PubMed ID: 35678444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Similarities and differences in the oncology drug approval process between FDA and European Union with emphasis on in vitro companion diagnostics.
    Senderowicz AM; Pfaff O
    Clin Cancer Res; 2014 Mar; 20(6):1445-52. PubMed ID: 24634467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical device regulation for manufacturers.
    McAllister P; Jeswiet J
    Proc Inst Mech Eng H; 2003; 217(6):459-67. PubMed ID: 14702983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Study on Regulations of Exemption in Medical Device Registration and Approval Process in the United States and China].
    Hu K; Yang H
    Zhongguo Yi Liao Qi Xie Za Zhi; 2019 Mar; 43(2):122-125. PubMed ID: 30977611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medical Device Regulation: A Comparison of the United States and the European Union.
    Maak TG; Wylie JD
    J Am Acad Orthop Surg; 2016 Aug; 24(8):537-43. PubMed ID: 27195383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors That Facilitate Regulatory Approval for Drug-Device Combination Products in the European Union and United States of America: A Mixed Method Study of Industry Views.
    Masterson F
    Ther Innov Regul Sci; 2018 Jul; 52(4):489-498. PubMed ID: 29714544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Comparative Review of Marketing Authorization Decisions in Switzerland, the EU, and the USA.
    Dalla Torre Di Sanguinetto S; Heinonen E; Antonov J; Bolte C
    Ther Innov Regul Sci; 2019 Jan; 53(1):86-94. PubMed ID: 29714594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Introduction of Quality Management System Audit in Medical Device Single Audit Program].
    Wen J; Xiao J; Wang A
    Zhongguo Yi Liao Qi Xie Za Zhi; 2018 Jan; 42(1):53-55. PubMed ID: 29862748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The legal framework governing the quality of (traditional) herbal medicinal products in the European Union.
    Kroes BH
    J Ethnopharmacol; 2014 Dec; 158 Pt B():449-53. PubMed ID: 25086408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hurdles of environmental risk assessment procedures for advanced therapy medicinal products: comparison between the European Union and the United States.
    Iglesias-Lopez C; Obach M; Vallano A; Agustí A; Montané J
    Crit Rev Toxicol; 2019 Aug; 49(7):580-596. PubMed ID: 31846383
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-clinical Post-Marketing Commitments for newly licenced pharmaceuticals.
    Reeve LM
    Regul Toxicol Pharmacol; 2009 Nov; 55(2):181-7. PubMed ID: 19589365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Introduction of innovative high-risk medical devices in Europe: are clinical efficacy and safety guaranteed?].
    Stordeur S; Vinck I; Neyt M; Van Brabandt H; Hulstaert F
    Rev Epidemiol Sante Publique; 2013 Apr; 61(2):105-10. PubMed ID: 23477881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.